alive and kicking
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Will wonders never cease! ENTA is up for the 3rd day in a row and closed over $22. Still a long, long way to go but it feels nice to see some positive sentiment.
Happy Independence Day! Well, it isn't July 4th yet but I took today off to give myself a 4 day weekend. :)
Will wonders never cease! ENTA is up for the 3rd day in a row and closed over $22. Still a long, long way to go but it feels nice to see some positive sentiment.
Happy Independence Day!
One can never pick a bottom but regardless of what the broader market is doing, the fact remains that EDP-235 phase 2 data was quite good. I continue to buy in small amounts and have now increased my shares by 33% since the phase 2 data release. The views of the general public on ENTA are meaningless to me. Some apparently “think” deals can be worked out in a matter of weeks, which is nonsense.
With ENTA stock continuing to take a beating, I thought I would explain why I remain bullish and a buyer.
The EDP-235 data was quite good. It showed a good safety profile, showed a statistically significant improvement in symptoms and reducing their duration, in a highly vaccinated low risk population that had mostly been previously infected. In stark contrast, Paxlovid failed to do that in an similar low risk population, but one in which most were not yet vaccinated or infected. Despite this effectiveness in improving symptoms, the knock that drove ENTA down was the lack of viral reduction in nasal swabs, even though nasal swabs isn't a metric for approval and Remdesivir didn't do that either yet got FDA approval.
That left the conundrum of why EDP-235 showed robust anti-viral effects with regards to symptoms but not in nasal viral swabs. The anomaly was a rapid decreases nasal swab viral levels in the control group, possibly due to previous infection with Covid generating strong IgM responses. That would explain the rapid clearance in mucosal membranes in controls. ENTA looked closely and saw that if they examined patients who hadn't been previously infected, those without anti-nucleocapsid antibodies, there was indeed a robust viral reduction with EDP-235. Given that the vast majority in the EDP-235 phase 2 trial had been previously infected, that would explain why no difference was seen. The general population doesn't care but prospective partners will be assured. I know I am.
Rwwine, I am never surprised at shortsightedness and fear driving a stock down, or for that matter the stock market.
Most Biotech stocks took a beating today. Did they all have bad news? Obviously not.
I have a lot of confidence in ENTA given how impressive the EDP-235 phase 2 trial data was.
I just love it when the market lets me buy stocks I like at a discount. I have already increased my shares of ENTA by 25% since its drop after the successful EDP-235 phase 2 trial. I will be buying more.
I just love it when the market lets me buy stocks I like at a discount. I have already increased my shares of ENTA by 25% since its drop after the successful EDP-235 phase 2 trial. I will buy more
It is amazing to watch IMGN stock price go up day after day. I am a long time IMGN shareholder so you can be sure that pleases me, but it is still amazing to see.